Clinical Trial Update: Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction [Phase 2]

View source ↗

Summary

This clinical trial update notes a Phase 2 study of adjuvant trastuzumab deruxtecan (Enhertu) in combination with nivolumab for patients who are disease-free af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• OPDIVO (nivolumab)

Snippet

Sponsor: Brown University | Conditions: Esophageal Adenocarcinoma, Esophageal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING